Valuation : Avicanna Inc.

Market Cap 17.9M 12.91M 11.09M 10.38M 9.5M 1.23B 17.95M 123M 48.04M 622M 48.49M 47.44M 2.06B P/E 2024
-8.43x
P/E 2025 -9.36x
Enterprise Value 17.62M 12.71M 10.91M 10.22M 9.35M 1.21B 17.67M 121M 47.29M 612M 47.73M 46.7M 2.03B EV / Sales 2024
1.31x
EV / Sales 2025 1.03x
Free-Float
76.29%
Yield 2024 *
-
Yield 2025 -
1 day-6.91%
1 week-3.37%
Current month-1.94%
1 month-5.41%
3 months-4.11%
6 months-34.23%
Current year-43.92%
1 week 0.09
Extreme 0.08691
0.1
1 month 0.09
Extreme 0.0853
0.1
Current year 0.07
Extreme 0.06842
0.18
1 year 0.07
Extreme 0.06842
0.24
3 years 0.07
Extreme 0.06842
0.53
5 years 0.07
Extreme 0.06842
1.02
10 years 0
Extreme 0
3.53
Manager TitleAgeSince
Sales & Marketing - 30/04/2015
Chief Executive Officer 39 25/11/2016
Director of Finance/CFO - 14/09/2025
Director TitleAgeSince
Chairman 39 25/11/2016
Director/Board Member - 21/10/2018
Director/Board Member - 31/12/2025
Change 5-day change 1-year change 3-year change Capi.($)
-6.91%-3.37% - - 12.89M
+0.10%+0.44%+2.80%+24.32% 50.96B
+2.65%+4.45%+481.36%+567.32% 46.18B
+0.33%+2.47%+38.97%+19.80% 43.04B
-0.88%+0.90%+24.11%+87.74% 42.73B
-2.27%-3.02%+14.22%+51.50% 33.48B
-1.21%-0.17%+29.16%+135.38% 17.28B
-0.36%-2.14% - - 16.43B
+0.25%+0.25%+12.03%+30.68% 14.73B
+0.44%+1.70%+82.07%+47.92% 14.09B
Average -0.79%+0.34%+85.59%+120.58% 30.99B
Weighted average by Cap. +0.04%+0.57%+104.35%+141.83%

Financials

2024 2025
Net sales 25.46M 18.37M 15.76M 14.76M 13.51M 1.75B 25.53M 175M 68.32M 884M 68.95M 67.46M 2.93B 25.48M 18.38M 15.78M 14.77M 13.53M 1.76B 25.55M 175M 68.37M 885M 69.01M 67.51M 2.93B
Net income -3.62M -2.61M -2.24M -2.1M -1.92M -249M -3.63M -24.83M -9.71M -126M -9.8M -9.59M -416M -2.76M -1.99M -1.71M -1.6M -1.46M -190M -2.77M -18.94M -7.4M -95.81M -7.47M -7.31M -317M
Net Debt -339K -244K -210K -196K -180K -23.34M -340K -2.33M -909K -11.76M -918K -898K -38.93M -281K -202K -174K -163K -149K -19.33M -281K -1.93M -753K -9.74M -760K -744K -32.25M
Logo Avicanna Inc.
Avicanna Inc. is a commercial-stage international biopharmaceutical company. It focuses on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Its products and services are grouped into four main categories, such as medical cannabis products; MyMedi.ca medical cannabis platform; pharmaceutical pipeline; and active pharmaceutical ingredients. The formulary of proprietary medical cannabis products is marketed under the RHO Phyto brand and offers a range of scientifically driven formulations in a variety of products, including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids. MyMedi.ca offers a diverse portfolio of products and bilingual pharmacist-led patient support programs. It has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. Trunerox is its oral formulation.
Employees
112
Date Price Change Volume
27/08/26 US$0.0909 -6.91% 300
26/08/26 US$0.0976 +2.95% 7,225
25/08/26 US$0.0948 +3.20% 500
24/08/26 US$0.0919 -5.69% 46,213
21/08/26 US$0.0974 +3.54% 8,300